The recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) in the scatter factor family, which includes the c-Met receptor. RON exhibits increased expression in a significant number of human breast cancer tissues as well as in many established breast cancer cell lines. Recent studies have indicated that in addition to ligand-dependent signaling events, RON also promotes signals in the absence of its only known ligand, MSP, when expressed in epithelial cells. In this study, we found that when expressed in MCF-10A breast epithelial cells, RON exhibits both MSP-dependent and MSP-independent signaling, which lead to distinct biological outcomes. In the absence of MSP, RON signaling promotes cell survival, increased cell spreading and enhanced migration in response to other growth factors. However, both RONmediated proliferation and migration require the addition of MSP in MCF-10A cells. Both MSP-dependent and MSP-independent signaling by RON are mediated in part by Src family kinases. These data suggest that RON has two alternative modes of signaling that can contribute to oncogenic behavior in normal breast epithelial cells.
Introduction
The receptor tyrosine kinase (RTK) recepteur d'origine nantais (RON) is a member of the c-Met family of scatter factor receptors. (Ronsin et al., 1993) . After binding to its only known ligand, the macrophage stimulating protein (MSP), RON promotes activation of the PI3K/AKT, MAPK and b-catenin pathways, among others (Wang et al., 2003) . Increased levels of RON expression have been found in several epithelial human tumors including colon (Chen et al., 2000) , pancreatic (Thomas et al., 2007) and breast cancers (Maggiora et al., 1998) . Furthermore, clinical studies indicate that increased expression of RON in both human bladder and breast carcinomas correlates with more aggressive disease and poor patient prognosis (Lee et al., 2005; Hsu et al., 2006) . Recent studies showed that a monoclonal antibody that blocks RON activation by MSP also inhibited the growth of human tumor xenographs in mice, indicating that signaling by RON played a role in tumor growth (O'Toole et al., 2006) . Together, these studies provide evidence that RON may play a general role in cancer development.
RON appears to play a significant role in breast cancer. Nearly 47% of primary human breast cancers expressed RON, and increased expression of RON was found in established breast cancer cell lines (Maggiora et al., 1998) . In addition, when mice were engineered to express RON in mammary tissue, 100% of the RONexpressing mice developed tumors, whereas the parental mice did not develop tumors (Zinser et al., 2006) Although increased expression of RON in breast carcinomas is well documented, whether RON can promote cancer progression in the absence of MSP is less well understood. To date, no naturally occurring mutations of RON have been identified in human breast cancers; therefore, it is likely that interactions with other cell receptors or kinases might be responsible for the ligand-independent activation of RON.
In breast carcinomas, the activity of Src promotes tumor progression at least in part by its ability to synergize with the epidermal growth factor receptor (Wilson et al., 1989; Biscardi et al., 2000) . Other RTKs also interact with Src kinases to enhance oncogenic signaling in human cancers, including c-Met (Emaduddin et al., 2008) and platelet-derived growth factor receptor . In addition, Src mediated RON activation downstream of b1 integrins in human keratinocytes (Danilkovitch-Miagkova et al., 2000) . The fact that two or more kinases cooperate to increase their oncogenic effects may dramatically impact the clinical treatment for those patients whose tumors are co-expressing RTKs with other kinases (Stommel et al., 2007) .
As Src is highly expressed and deregulated in at least 70% of human breast cancers , it is likely that RON and Src are co-expressed in a number of breast tumors. Furthermore, Src is recognized as an important contributing factor to breast cancer progression . In this study, we examined the contributions of RON, and its putative interaction with c-Src, to the progression of breast cancer by expressing RON in the well-characterized MCF-10A human mammary epithelial cell line. MCF-10A cells are a powerful cell system with which to identify the effects of oncogenic signaling by RTKs (Muthuswamy et al., 2001; Debnath et al., 2003) . Our current research determined that the RON receptor was activated in the absence of MSP when expressed in MCF-10A cells, which gave rise to evasion of cell death, an increase in spreading and an increased migratory potential. MSP stimulation of RON was required for RON-mediated cell migration and proliferation, which suggests that MSP-independent functions of RON are not solely a consequence of increased RON expression levels. In addition, Src activity is required for RONmediated MSP-independent biologic effects. These data imply that RON cooperates with Src in mammary epithelial cells to promote cellular changes that may allow progression toward a fully oncogenic state.
Results
Characterization of RON expression levels in MCF-10A cells Endogenous levels of RON were low in the relatively normal epithelial cell line MCF-10A. Consequently, the cells did not respond to MSP in any biological or biochemical assays we have tested to date. Therefore, to examine the contributions of RON to the progression of breast cancer, we transduced MCF-10A cells with a retrovirus expressing wild-type human RON and internal ribosome entry site (IRES)-promoted green fluorescent protein (GFP). Pools of infected cells were selected for high, medium and low GFP expression levels by Fluorescence-Activated Cell Sorting (FACS), and, as expected, GFP levels were mimicked by expression levels of RON (Figure 1a) . We designated these cells as 10A/RON and our vector-only-negative control cell line was designated as 10A/Vector. The levels of RON expression in 10A/RON cells were well within the range of expression found in human breast carcinomas, some of which had RON levels that were up to 72-fold higher than the level found in benign tissue (Maggiora et al., 1998) . High, medium and low 10A/ RON cell lines behaved similarly in all of our experiments; therefore, we used the medium RON-expressing MCF-10A cell line throughout this study.
RON exhibits MSP-independent tyrosine phosphorylation in MCF-10A cells Although MSP is the only known ligand for RON, RON may not require MSP to induce some of its biological effects. For example, RON knockout mice die by E6.5 (Muraoka et al., 1999) , whereas mice deficient in MSP exhibit a nearly normal phenotype (Bezerra et al., 1998) . We detected MSP-independent tyrosine phosphorylation of RON using an anti-phospho-tyrosine antibody (Figure 1b Figure 1a) , indicating that the RON receptor is not constitutively active, but rather that the activation seen in MCF-10A cells is a cell-specific effect. MSP-independent tyrosine phosphorylation of RON is not unique to MCF-10A cells, as we can recapitulate the MSP-independent activation of RON by expressing RON in HeLa cells (Supplementary Figure 1b) . Furthermore, we found that a kinase dead mutant of RON, K1114M (Danilkovitch-Miagkova et al., 2000) , does not exhibit any tyrosine phosphorylation in HeLa cells (Supplementary Figure 2b) , providing evidence that the kinase activity of RON is necessary for phosphorylation.
MSP increases stimulation of MAPK and AKT but has no effect on the phosphorylation of FAK We considered possible molecular differences between MSP-dependent and MSP-independent RON signaling in MCF-10A cells by looking at the activation of MAPK (Erk 1/2) and AKT, which are known to be important for MSP-driven activation of RON in other cell systems. In the absence of MSP, RON promotes a low level of MAPK activation and a barely detectable AKT activation; however, MSP significantly increased the activation of both MAPK and AKT ( Figure 2a ). We also looked at whether a molecular distinction could be made in focal adhesion kinase (FAK) phosphorylation between MSP-dependent and MSP-independent RON signaling because of RON's known role in cell migration and its earlier described interaction with the Src kinase (Danilkovitch-Miagkova et al., 2000) , which has a role in FAK signaling. This data showed that in MCF-10A cells, FAK is constitutively phosphorylated and there was no discernible difference between 10A/Vector and 10A/RON cells in the presence or absence of MSP ( Figure 2b ).
Tyrosine phosphorylation of RON is Src dependent
Ligand-independent activation of RTKs can occur as a result of interaction with other cell surface receptors or other intracellular kinases. We considered whether the intracellular Src kinase was required for phosphorylation of RON in 10A/RON cells for three reasons: wildtype Src is frequently upregulated in breast cancers (Ottenhoff-Kalff et al., 1992) , it is known to enhance RTK signals in cancer (Tice et al., 1999) and Src was implicated in signaling by RON (Danilkovitch-Miagkova et al., 2000) . When Src activity was blocked with the inhibitor PP2, we found that both MSP-dependent and MSP-independent phosphorylation of RON was reduced, although in the presence of MSP, substantially more tyrosine phosphorylation of RON remained after PP2 treatment ( Figure 3a ). These data suggest that MSP stimulation of RON may promote the activation of additional Src-independent pathways compared with the pathways activated by MSP-independent signaling of RON. To extend these observations, we tested the effect of a dominant-negative mutant of Src (in which the Src active site lysine was mutated to arginine), on the tyrosine phosphorylation of RON in HeLa cells. MSPdependent and MSP-independent phosphorylation of RON were blocked when RON was co-transfected with the dominant-negative Src construct (Figure 3b ). These data suggest that Src family kinases play a general role in the tyrosine phosphorylation of RON in epithelial cells.
MSP-dependent and MSP-independent activation of RON give rise to distinct biological consequences RON-mediated proliferation requires MSP. MCF-10A cells require the addition of EGF to proliferate; therefore, by omitting EGF from the growth media, we determined whether 10A/RON cells could proliferate both in the presence and absence of MSP. Approximately 12% of 10A/RON cells were 5-bromo-2 0 -deoxyuridine (BrdU) positive when cultured without the addition of MSP or EGF compared with approximately 7% BrdU incorporation in 10A/Vector cells (Figure 4a ). In contrast, the addition of MSP to the media of 10A/RON cells led to approximately 30% BrdU incorporation whereas the 10A/Vector cells did not proliferate in response to MSP (Figure 4a ). Overall, 35% of both 10A/Vector and 10A/RON cells were BrdU positive with EGF. These data indicate that MSPindependent activation of RON is not sufficient for cell proliferation; however, because of the increased expression level of RON, MSP can act as a mitogen in 10A/ RON cells. Furthermore, the MSP-independent activation of RON does not appear to promote additive proliferative effects with epidermal growth factor receptor stimulation.
RON-mediated migration requires MSP. MSP stimulation of RON can increase epithelial cell migration; however, it is not clear whether RON-mediated migration can occur in the absence of MSP. Using Transwell filter migration assays, we confirmed that MSP induced migration in 10A/RON cells, but in the absence of MSP, 10A/RON cells did not significantly migrate (Figures 4b and c) . We conclude that MSP-independent RON activation is not sufficient to promote cell migration in the absence of basally added growth factors.
Both 10A/Vector and 10A/RON cells migrated in response to EGF; however, at 6 h after EGF addition, approximately 50% more of 10A/RON cells had migrated than 10A/Vector cells (Figure 4c) . A similar effect was seen 18 h after adding EGF, when approximately 27% more of 10A/RON cells migrated through the filter than 10A/Vector cells (Figure 4b ). To determine whether the increased migratory potential of 10A/RON cells was an EGF-specific phenomenon, we repeated the assay with the addition of the c-Met ligand, HGF, as MCF-10A cells express endogenous levels of Met (Montesano et al., 1998) . In this case, approximately 30% more of 10A/RON cells migrated in response to HGF than 10A/Vector cells within 6 h and approximately 60% more of 10A/RON cells migrated when cells were examined after 18 h of HGF treatment (Figures 4b and c) . These data suggest that although the MSP-independent activation of RON is not sufficient to promote migration on its own, the expression of RON in MCF-10A cells confers an intrinsic migratory advantage of these cells compared with 10A/Vector cells in response to EGF or HGF.
RON-mediated cell spreading is MSP independent. During the process of cell migration, cells must first adhere to the substratum and then spread before extending lamellipodia to propel them forward (Yamaguchi et al., 2005) . We hypothesized that if 10A/RON cells had an ability to adhere and/or spread more efficiently, it would explain the MSP-independent migratory advantage over the 10A/Vector cells. To test this possibility, we allowed the 10A/Vector and 10A/RON cells to briefly attach to poly-D-lysine-coated coverslips. After 10 min, the unattached cells were washed away and the remaining cells were fixed and stained with rhodamine-conjugated phalloidin to visualize the actin filaments. Attached cells exhibited two phenotypes: they were either columnar in shape, which indicated a very early point in the cell attachment process, or the cells were flattened and spread, indicating a more advanced stage in the sequence of adhesion events (Figure 5a ). The columnar cells were approximately 15-20 mm in diameter or less when measured, whereas spreading cells ranged from 20-40 mm in diameter (data not shown). We quantified the difference between 10A/Vector and 10A/RON cells and found that overall approximately 60% of 10A/RON cells exhibited a flattened appearance within 10 min as compared with approximately 20% spreading of the 10A/Vector cells (Figures 5b and d) . The addition of MSP to this assay did not increase the percentage of spreading 10A/RON cells. These data show that 10A/ RON cells have acquired an expanded ability to spread on this substratum.
RON-mediated evasion of cell death is MSP independent. MSP stimulation of RON has been associated with anti-apoptotic activity in epithelial cells . To examine whether RON can protect cells from cell death in the absence of MSP, we used a cell death assay in which we incubated cells in Dulbecco's modified Eagle's medium without added growth factors or serum for 72 h. Floating cells were collected from the media and pooled with the remaining adherent cells after they were removed from the plate by trypsinization. Dead cells were identified by propidium iodide (PI) labeling and the percentage of cell survival was assessed by FACS analysis. As seen in Figure 6a , only 7% of the 10A/Vector cells survived under these conditions in contrast to 31% of the 10A/RON cells. MSP minimally increased the survival rate to 34%. These data imply that MSP-independent activation of RON improves 10A/RON cell survival in the absence of growth factors, and that MSP does not significantly contribute to this effect. Figure 6b presents the phenotypic difference between 10A/Vector and 10A/RON cells when cultured without EGF. After 4 days, most of the 10A/Vector cells were rounded up, floating in the media, and stained positive for PI, whereas the 10A/RON cells remained strongly adherent and began to proliferate when growth factors were added to the media (data not shown). The MCF-10A cells undergoing cell death in our survival assay appear to be dying by apoptosis, as poly (ADP-ribose) polymerase is cleaved in these cells (Supplementary Figure 2b) . It was difficult to collect enough 10A/Vector cells for analysis, which is why it is not possible to distinguish the cleaved form of poly (ADP-ribose) polymerase in the 10A/Vector cells, but it is clear that poly (ADP-ribose) polymerase is cleaved in dying 10A/RON cells from this data.
Effects of kinase inhibitors on RON-mediated biological effects
As tyrosine phosphorylation of RON depends on the activity of Src family kinases (Figure 3) , we examined whether Src signaling is required for RON-mediated biological effects. We found that PP2 nearly abolished the increased survival of 10A/RON cells under serumstarved conditions regardless of whether MSP was added (Figure 6a ). PP2 treatment had no effect on 10A/Vector and 10A/RON cells cultured in regular growth media for 72 h (Supplementary Figure 2a) . RON-mediated cell spreading was also completely abrogated by PP2 both in the absence and presence of MSP (Figures 5c and d) . Src activity was not necessary for cell proliferation in response to EGF or MSP, as PP2 treatment did not influence BrdU incorporation (data not shown). However, PP2 abolished cell migration in response to either MSP or EGF (data not shown), which could potentially be owing to the effect of PP2 on cell attachment. We also determined the influence of PI3K/AKT (LY294002) and MEK/ERK (U0126) inhibitors on RON-mediated biological effects. In contrast to PP2, these inhibitors had no effects on cell spreading either with or without MSP. These two inhibitors did, however, completely abrogate the cell survival properties of RON and reduced MSP-induced Transwell migration by 60-80% (data not shown). These data imply the activity of Src family kinases that are required for RON-mediated MSP-independent events, but it remains unclear if all MSP-mediated events also depend on Src.
Discussion
Our study describes a novel and significant role for MSP-independent RON signaling in cell spreading and evasion of cell death. We found that increased expression of RON in breast epithelial cells leads to both MSPdependent and MSP-independent biological events. In the absence of MSP, RON promoted an increase in cell spreading, cell survival and enhanced growth factormediated migration in MCF-10A cells. However, MSP was required to induce RON-mediated migration and proliferation, implying that RON possesses two distinct modes of signaling. Furthermore, we found that Src family kinases contribute to the activity of RON both in the presence and absence of MSP. Ligand-independent activation of non-mutated RTKs is commonly because of increased expression that allows unregulated receptor dimerization and activation, promoting tumor development (Weiss et al., 1997) . In epithelial cells that express high amounts of c-Met, cell attachment mediates ligand-independent tyrosine phosphorylation of c-Met (Wang et al., 1996 (Wang et al., , 2001 ). In our study, we did not find that MSP-independent tyrosine phosphorylation of RON was a direct result of cell attachment (data not shown). However, we found that 10A/RON cells exhibited a significant increase in cell attachment and spreading compared with 10A/Vector cells, suggesting that cell adhesion may generally regulate the scatter factor receptors.
We hypothesize that the increased adhesive and spreading property of 10A/RON cells explains their enhanced migratory response toward EGF and HGF, as well as their ability to avoid cell death under serumstarved conditions. During migration, 10A/RON cells may attach to the filter more quickly than 10A/Vector cells, allowing for more efficient movement through the pores. Cell adhesion itself activates survival pathways through integrins or other cell surface receptors (Hofmann et al., 2007; Kang et al., 2007; Muller et al., 2008) . The ability of cells to evade intrinsic cell death pathways is a major contributor to tumor development (Mehlen and Puisieux, 2006 ). Even at the lowest level of RON expression, at least 30% of 10A/RON cells survived serum-free conditions compared with almost no survival of the 10A/Vector cells. It is not known whether the adhesion effects are mediated by interactions of RON with receptors such as integrins. MCF-10A cells have been reported to secrete laminin 5 (Stahl et al., 1997; and our own unpublished results) . RON is known to interact with b1 integrins (DanilkovitchMiagkova et al., 2000; Santoro et al., 2003) , one of the receptors for laminin 5; however, we could not show that 10A/RON cells bound more strongly to laminin 5 than did 10A/Vector cells (data not shown).
Src mediates a diverse range of biological process downstream of RTKs, such as cell survival (Yamamoto et al., 2006) , proliferation (Riggins et al., 2006) , adhesion and migration (Van Slambrouck et al., 2007) . Furthermore, RON signals through Src downstream of integrins (Danilkovitch-Miagkova et al., 2000) and Src was responsible for RON-mediated constitutive activation of MAPK in the absence of MSP (Wei et al., 2005) . Our data confirms that Src family kinases play a significant role in both MSP-dependent and MSPindependent RON signaling. We found that inhibition of Src family kinases reduced tyrosine phosphorylation of RON and abrogated RON-mediated biological events, with the exception of cell proliferation, implying that RON uses a Src-independent pathway to mediate proliferation in MCF-10A cells. In the case of epidermal growth factor receptor, Src mediates EGF-independent transactivation, which promotes differential biological effects than that of EGF stimulation of epidermal growth factor receptor (Moro et al., 2002; Wu et al., 2002) This is similar to the observations reported here on the MSP-independent activation of RON.
In the presence of MSP, RON activates the MAPK and PI3K pathways (Danilkovitch-Miagkova, 2003; and Figure 2) . We found that MSP-independent signaling by RON also activates MAPK ( Figure 2) ; however, the reduced level of stimulation was not sufficient for RONmediated proliferation or migration. To examine the role of these pathways further, we used the inhibitor LY294002 to block PI3K/AKT or U0126 to block MEK/ERK. These pathways were not clearly involved in cell spreading, but played a role in MSP-dependent and MSP-independent cell survival and also in MSP-induced migration. In addition to MAPK and AKT, there is also the potential that MSP regulates additional or alternative signaling pathways to MSP-independent signaling.
MSP stimulation of RON induces conformational changes (Yokoyama et al., 2005) that could potentially expose alternative residues to activate distinct pathways, or alter the signal intensity and duration. MSP activation of RON increased phosphorylation of the docking site Y1360 as well as Y1238/1239 in the catalytic domain (Figure 1c ), implying that some structural changes do occur in the presence of MSP. In the mouse RON receptor, docking site tyrosines of RON were required for MSP-independent activation of MAPK, but were dispensable for MSP-induced MAPK activation (Wei et al., 2005) . A future comprehensive analysis of human RON tyrosine phosphorylation sites would appear merited. RON activation in cancer is thought to be a late stage event because of its roles in migration, invasion and development of an epithelial-to-mesenchymal transition (EMT) in tissue culture (Wang et al., 2004; Cote et al., 2007) . We propose that in early stage breast cancers, co-expression of Src and RON is sufficient to initiate oncogenic behavior in the absence of MSP. In support of this, one recent study concluded that co-expression of RON, MSP and the MSPactivating enzyme (MT-SP1) was a strong prognostic marker for a poor patient survival; however, less than 20% of the samples actually exhibited expression of all three mRNAs (Welm et al., 2007) . Nonetheless, clinical studies have shown that RON expression alone is predictive for poor patient prognosis in breast cancers (Lee et al., 2005) . Taken together, these data offer two major implications: first, in the majority of RONexpressing breast cancers, RON contributes to oncogenicity in the absence of activated MSP and the second implication is that RON expression and its ligandindependent signaling in breast cancer are early events, and that the later stage disease is characterized by further activation of MSP and MT-SP1.
Nearly, all cancer deaths stem from metastatic growths rather than the primary tumors (Mehlen and Puisieux, 2006) , and therefore, it is critical to design cancer therapies that target events occurring in early stages of cancer to prevent secondary growths. Several therapeutic strategies have recently been developed to target RTKs in human cancers. These agents are either small molecule inhibitors that block RTK activity or monoclonal antibodies that bind to the RTK and inhibit its signaling (Tagliaferri et al., 2005) . Both of these molecular approaches have proven to be clinically successful in many cases; however, strategies targeting the extracellular ligand-binding domain of RTKs may not be successful in treating patients whose tumors exhibit signaling in the absence of ligand. We provide evidence that in the case of RON-expressing mammary tumors, targeting Src in addition to RON could potentially reduce oncogenic behaviors.
Materials and methods

Materials and antibodies
MSP and the anti-MSP receptor antibody were from R&D Systems (Minneapolis, MN, USA). EGF was from Peprotech (Rocky Hill, NJ, USA). HGF was a gift from Amgen (Thousand Oaks, CA, USA). Poly-D-lysine (P6407), PI (P4864) and anti-BrdU antibody (Clone BU-33) were from Sigma-Aldrich (St Louis, MO, USA). AlexaFluor 546 (A11030), rhodamine-phalloidin (R415) and Hoechst 33342 were from Molecular Probes/Invitrogen (Eugene, OR, USA). Antibodies for western blots were as follows: 4G10 and anti-MAPK from Upstate Biotechnology Inc. (Lake Placid, NY, USA), anti-phospho-MAPK and anti-FAK from BD Transduction Laboratories (San Diego, CA, USA), anti-RON (sc-22) and all anti-phospho-RON rabbit polyclonal antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), anti-phospho-AKT was from Cell Signaling (Danvers, MA, USA) and PP2 was from BioMol (Plymouth Meeting, PA, USA).
Cell culture
Cell culture materials were purchased from Gibco/Invitrogen (Carlsbad, CA, USA). NIH-3T3 and HeLa cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and antibiotics. 10A/Vector and 10A/RON cells were cultured as described (Debnath et al., 2003) . pUSE-DNSrc, was provided by Dr WT Miller (SUNY StonyBrook). HeLa cells were transfected with Fugene (Roche Applied Science, Indianapolis, IN, USA). The K1114M RON mutant was generated using a GeneEditor mutagenesis kit (Promega, Madison, WI, USA) with an earlier reported oligonucleotide (Danilkovitch-Miagkova et al., 2000) .
Generation of MCF-10A/RON cell lines
Retroviruses expressing wild-type human RON were generated by transfection of Phoenix E cells with REBNA-RON-IRES-GFP retroviral vector (Petrenko et al., 1999) . Virus-containing supernatant from the Phoenix E cells was added to MCF-10A/ ecoR cells for 6 h. For more information, see the Nolan Laboratory website for further details on generating retroviruses with the Phoenix E cell system (http://www.stanford. edu/group/nolan/index.html).
Proliferation assays
Cells were cultured on coverslips for 48 h in specified media, pulsed with BrdU for 2 h, washed with phosphate-buffered saline, fixed with methanol and treated with 4N HCl for 30 min. BrdU was labeled with an anti-BrdU antibody and detected using AlexaFluor 546 secondary antibody. The percentage of BrdU-positive cells was determined by counting at least 500 cells per coverslip.
Transwell migration assay Cells were starved overnight in Dulbecco's modified Eagle's medium/F-12 media containing 1% horse serum. A total of 100 000 cells were added to the top well of a 24-well, 0.8-mm pore Transwell filter insert (Costar, Corning, NY, USA). Media added to the bottom well contained no growth factors, 10 ng/ml EGF, 100 ng/ml MSP or 2 ng/ml HGF. After 6 or 18 h, cells that remained in the top chamber were removed with a cotton swab, the migrated cells were fixed, and DNA was labeled with Hoechst. The number of migrating cells per field of view was counted on a fluorescent microscope under a Â 20 magnification.
Immunoblotting All immunoprecipitations and immunoblots were performed as described (Yokoyama et al., 2005 ) using a 9% polyacrylamide gel.
Apoptosis assay
Cells were stained with PI and the percentage of PI-positive cells was determined using a BD FACSCalibur system (BD, Franklin Lakes, NJ, USA). PP2 was added to the cultures after the cells were allowed to settle on the dish overnight.
Adhesion and attachment assays Cells were incubated on poly-D-lysine-coated coverslips in Dulbecco's modified Eagle's medium for 10 min. Unbound cells were washed away with phosphate-buffered saline. Attached cells were fixed with 3.7% paraformaldehyde for 15 min at 4 1C, incubated with 0.1% Triton X-100 for 2 min and rhodamine-conjugated phalloidin was added according to the commercial protocol. Cells were visualized with an Axiovert 200M (Zeiss, Thornwood, NY, USA) using a 63X oil DIC lens and the images were analysed using the Axiovision software (Zeiss).
Reverse transcriptase-PCR Cellular RNA was isolated with RNeasy kit (Qiagen, Valencia, CA, USA), and reverse transcribed to cDNA using the Superscript II reverse transcriptase system (Invitrogen, Carlsbad, CA, USA). MSP was detected using primers described earlier (Zalcenstein et al., 2006) .
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